Moreover, insulin and rosiglitazone have been reported to potentially influence bladder cancer risks54,55, this likely leads to the incorrect estimation of the association between pioglitazone use and bladder cancer risk. The gene discussed is INS; the disease is urinary bladder carcinoma.